Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1
Background. Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1. Methods. Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, mult...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2010-10, Vol.51 (7), p.833-843 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 843 |
|---|---|
| container_issue | 7 |
| container_start_page | 833 |
| container_title | Clinical infectious diseases |
| container_volume | 51 |
| creator | Burgard, M. Jasseron, C. Matheron, S. Damond, F. Hamrene, K. Blanche, S. Faye, A. Rouzioux, C. Warszawski, J. Mandelbrot, L. |
| description | Background. Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1. Methods. Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007. Results. Overall, 2.6% (223/8660) of mothers were infected with HIV-2, and they accounted for 3.1% (367/11841) of the total births. Most were born in sub-Saharan Africa. A higher proportion of HIV-2-infected mothers than HIV-1-infected mothers had no symptoms, had received no antiretroviral threrapy at conception (85.9% vs 66.7%), and had received no antiretroviral therapy during pregnancy (42.8% vs 19.9%), particularly highly active antiretroviral therapy (HAART) (79.7% vs 46.1%), and they had higher CD4 cell counts near delivery (median, 574 vs 452 cells/mm3; P < .01). If antiretroviral therapy was used, it was started at a later gestational age for HIV-2-infected mothers (median, 28 vs 25 weeks; P < .01). HIV-2-infected mothers were more likely to deliver vaginally (67.9% vs 49.3%) and to breastfeed (3.6% vs 0.6%; P < .01), and their infants less frequently received postexposure prophylaxis. In the period 2000–2007, the proportion with viral load |
| doi_str_mv | 10.1086/656284 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_888114670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>25742282</jstor_id><oup_id>10.1086/656284</oup_id><sourcerecordid>25742282</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-75fa730e21b8cd5a4de729ec44b194d395b27fe3504d8b76970debbc783742e13</originalsourceid><addsrcrecordid>eNqF0V1rFDEUBuBBFFur_gMlFapX0Xwnc1mGbneh2qKriDchk8mws85M1iQD9t-bddYWBPEqIefhPZyconiO0VuMlHgnuCCKPSiOMacSCl7ih_mOuIJMUXVUPIlxixDGCvHHxRFBCjGG6XExvPdp4wJMHlabrm_AOpgxDl2MnR-Bb8Fy9QUSsBpbZ9P-qQ1-ALhUAiQPCEISdCPIEeD8w8dPYBHcaDfgxoVuNMn0oPIbHxK4uFnA6ho_LR61po_u2eE8KT4vLtbVEl5dX66q8ytoOccJSt4aSZEjuFa24YY1TpLSWcZqXLKGlrwmsnWUI9aoWopSosbVtZWKSkYcpifFmzl3F_yPycWk80TW9b0ZnZ-iVkphzIRE_5WSM4R4yUWWr_6SWz-FMY-REVaCMUIyej0jG3yMwbV6F7rBhFuNkd4vSs-LyvDlIW2qB9fcsT-byeDsAEy0pm_zWmwX7x0llCq173g6Oz_t_t3sxWy2Mflwn8Hzb5HfGXCudzG5n3d1E75rIankevn1m1bLxSVXZK0R_QVX37cY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>751864422</pqid></control><display><type>article</type><title>Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Burgard, M. ; Jasseron, C. ; Matheron, S. ; Damond, F. ; Hamrene, K. ; Blanche, S. ; Faye, A. ; Rouzioux, C. ; Warszawski, J. ; Mandelbrot, L.</creator><creatorcontrib>Burgard, M. ; Jasseron, C. ; Matheron, S. ; Damond, F. ; Hamrene, K. ; Blanche, S. ; Faye, A. ; Rouzioux, C. ; Warszawski, J. ; Mandelbrot, L. ; ANRS French Perinatal Cohort EPF-CO1</creatorcontrib><description>Background. Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1. Methods. Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007. Results. Overall, 2.6% (223/8660) of mothers were infected with HIV-2, and they accounted for 3.1% (367/11841) of the total births. Most were born in sub-Saharan Africa. A higher proportion of HIV-2-infected mothers than HIV-1-infected mothers had no symptoms, had received no antiretroviral threrapy at conception (85.9% vs 66.7%), and had received no antiretroviral therapy during pregnancy (42.8% vs 19.9%), particularly highly active antiretroviral therapy (HAART) (79.7% vs 46.1%), and they had higher CD4 cell counts near delivery (median, 574 vs 452 cells/mm3; P < .01). If antiretroviral therapy was used, it was started at a later gestational age for HIV-2-infected mothers (median, 28 vs 25 weeks; P < .01). HIV-2-infected mothers were more likely to deliver vaginally (67.9% vs 49.3%) and to breastfeed (3.6% vs 0.6%; P < .01), and their infants less frequently received postexposure prophylaxis. In the period 2000–2007, the proportion with viral load <100 copies/mL at delivery was 90.5% of HIV-2-infected mothers, compared with 76.2% of HIV-1-infected mothers (P = .1). There were 2 cases of transmission: 1 case in 1993 occurred following maternal primary infection, and the other case occurred postnatally in 2002 and involved a mother with severe immune deficiency. The mother-to-child transmission rate for HIV-2 was 0.6% (95% confidence interval, 0.07%–2.2%). Conclusions. Care for HIV-2-infected pregnant women rests on expert opinion. The mother-to-child transmission residual rate (0.07%–2.2%) argues for systematic treatment: protease inhibitor-based HAART for women requiring antiretroviral therapy or for primary infection and simplified prevention of mother-to-child transmission in other instances.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/656284</identifier><identifier>PMID: 20804413</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: The University of Chicago Press</publisher><subject>Adult ; AIDS ; Antiretroviral drugs ; Biological and medical sciences ; Cohort Studies ; Disease transmission ; Drug therapy ; Female ; France ; Highly active antiretroviral therapy ; HIV ; HIV 1 ; HIV 2 ; HIV Infections - transmission ; HIV Infections - virology ; HIV-2 - isolation & purification ; HIV/AIDS ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Human immunodeficiency virus 2 ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infections ; Infectious Disease Transmission, Vertical ; Infectious diseases ; Maternal & child health ; Medical sciences ; Mothers ; Pregnancy ; Pregnancy Complications, Infectious - virology ; Protease inhibitors ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral load</subject><ispartof>Clinical infectious diseases, 2010-10, Vol.51 (7), p.833-843</ispartof><rights>2010 Infectious Diseases Society of America</rights><rights>2010 by the Infectious Diseases Society of America 2010</rights><rights>2015 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Oct 1, 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-75fa730e21b8cd5a4de729ec44b194d395b27fe3504d8b76970debbc783742e13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/25742282$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/25742282$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23233882$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20804413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burgard, M.</creatorcontrib><creatorcontrib>Jasseron, C.</creatorcontrib><creatorcontrib>Matheron, S.</creatorcontrib><creatorcontrib>Damond, F.</creatorcontrib><creatorcontrib>Hamrene, K.</creatorcontrib><creatorcontrib>Blanche, S.</creatorcontrib><creatorcontrib>Faye, A.</creatorcontrib><creatorcontrib>Rouzioux, C.</creatorcontrib><creatorcontrib>Warszawski, J.</creatorcontrib><creatorcontrib>Mandelbrot, L.</creatorcontrib><creatorcontrib>ANRS French Perinatal Cohort EPF-CO1</creatorcontrib><title>Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Background. Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1. Methods. Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007. Results. Overall, 2.6% (223/8660) of mothers were infected with HIV-2, and they accounted for 3.1% (367/11841) of the total births. Most were born in sub-Saharan Africa. A higher proportion of HIV-2-infected mothers than HIV-1-infected mothers had no symptoms, had received no antiretroviral threrapy at conception (85.9% vs 66.7%), and had received no antiretroviral therapy during pregnancy (42.8% vs 19.9%), particularly highly active antiretroviral therapy (HAART) (79.7% vs 46.1%), and they had higher CD4 cell counts near delivery (median, 574 vs 452 cells/mm3; P < .01). If antiretroviral therapy was used, it was started at a later gestational age for HIV-2-infected mothers (median, 28 vs 25 weeks; P < .01). HIV-2-infected mothers were more likely to deliver vaginally (67.9% vs 49.3%) and to breastfeed (3.6% vs 0.6%; P < .01), and their infants less frequently received postexposure prophylaxis. In the period 2000–2007, the proportion with viral load <100 copies/mL at delivery was 90.5% of HIV-2-infected mothers, compared with 76.2% of HIV-1-infected mothers (P = .1). There were 2 cases of transmission: 1 case in 1993 occurred following maternal primary infection, and the other case occurred postnatally in 2002 and involved a mother with severe immune deficiency. The mother-to-child transmission rate for HIV-2 was 0.6% (95% confidence interval, 0.07%–2.2%). Conclusions. Care for HIV-2-infected pregnant women rests on expert opinion. The mother-to-child transmission residual rate (0.07%–2.2%) argues for systematic treatment: protease inhibitor-based HAART for women requiring antiretroviral therapy or for primary infection and simplified prevention of mother-to-child transmission in other instances.</description><subject>Adult</subject><subject>AIDS</subject><subject>Antiretroviral drugs</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Disease transmission</subject><subject>Drug therapy</subject><subject>Female</subject><subject>France</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV 1</subject><subject>HIV 2</subject><subject>HIV Infections - transmission</subject><subject>HIV Infections - virology</subject><subject>HIV-2 - isolation & purification</subject><subject>HIV/AIDS</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Human immunodeficiency virus 2</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infections</subject><subject>Infectious Disease Transmission, Vertical</subject><subject>Infectious diseases</subject><subject>Maternal & child health</subject><subject>Medical sciences</subject><subject>Mothers</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - virology</subject><subject>Protease inhibitors</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral load</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0V1rFDEUBuBBFFur_gMlFapX0Xwnc1mGbneh2qKriDchk8mws85M1iQD9t-bddYWBPEqIefhPZyconiO0VuMlHgnuCCKPSiOMacSCl7ih_mOuIJMUXVUPIlxixDGCvHHxRFBCjGG6XExvPdp4wJMHlabrm_AOpgxDl2MnR-Bb8Fy9QUSsBpbZ9P-qQ1-ALhUAiQPCEISdCPIEeD8w8dPYBHcaDfgxoVuNMn0oPIbHxK4uFnA6ho_LR61po_u2eE8KT4vLtbVEl5dX66q8ytoOccJSt4aSZEjuFa24YY1TpLSWcZqXLKGlrwmsnWUI9aoWopSosbVtZWKSkYcpifFmzl3F_yPycWk80TW9b0ZnZ-iVkphzIRE_5WSM4R4yUWWr_6SWz-FMY-REVaCMUIyej0jG3yMwbV6F7rBhFuNkd4vSs-LyvDlIW2qB9fcsT-byeDsAEy0pm_zWmwX7x0llCq173g6Oz_t_t3sxWy2Mflwn8Hzb5HfGXCudzG5n3d1E75rIankevn1m1bLxSVXZK0R_QVX37cY</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>Burgard, M.</creator><creator>Jasseron, C.</creator><creator>Matheron, S.</creator><creator>Damond, F.</creator><creator>Hamrene, K.</creator><creator>Blanche, S.</creator><creator>Faye, A.</creator><creator>Rouzioux, C.</creator><creator>Warszawski, J.</creator><creator>Mandelbrot, L.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>7U2</scope></search><sort><creationdate>20101001</creationdate><title>Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1</title><author>Burgard, M. ; Jasseron, C. ; Matheron, S. ; Damond, F. ; Hamrene, K. ; Blanche, S. ; Faye, A. ; Rouzioux, C. ; Warszawski, J. ; Mandelbrot, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-75fa730e21b8cd5a4de729ec44b194d395b27fe3504d8b76970debbc783742e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>Antiretroviral drugs</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Disease transmission</topic><topic>Drug therapy</topic><topic>Female</topic><topic>France</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV 1</topic><topic>HIV 2</topic><topic>HIV Infections - transmission</topic><topic>HIV Infections - virology</topic><topic>HIV-2 - isolation & purification</topic><topic>HIV/AIDS</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Human immunodeficiency virus 2</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infections</topic><topic>Infectious Disease Transmission, Vertical</topic><topic>Infectious diseases</topic><topic>Maternal & child health</topic><topic>Medical sciences</topic><topic>Mothers</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - virology</topic><topic>Protease inhibitors</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burgard, M.</creatorcontrib><creatorcontrib>Jasseron, C.</creatorcontrib><creatorcontrib>Matheron, S.</creatorcontrib><creatorcontrib>Damond, F.</creatorcontrib><creatorcontrib>Hamrene, K.</creatorcontrib><creatorcontrib>Blanche, S.</creatorcontrib><creatorcontrib>Faye, A.</creatorcontrib><creatorcontrib>Rouzioux, C.</creatorcontrib><creatorcontrib>Warszawski, J.</creatorcontrib><creatorcontrib>Mandelbrot, L.</creatorcontrib><creatorcontrib>ANRS French Perinatal Cohort EPF-CO1</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burgard, M.</au><au>Jasseron, C.</au><au>Matheron, S.</au><au>Damond, F.</au><au>Hamrene, K.</au><au>Blanche, S.</au><au>Faye, A.</au><au>Rouzioux, C.</au><au>Warszawski, J.</au><au>Mandelbrot, L.</au><aucorp>ANRS French Perinatal Cohort EPF-CO1</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>51</volume><issue>7</issue><spage>833</spage><epage>843</epage><pages>833-843</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Background. Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1. Methods. Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007. Results. Overall, 2.6% (223/8660) of mothers were infected with HIV-2, and they accounted for 3.1% (367/11841) of the total births. Most were born in sub-Saharan Africa. A higher proportion of HIV-2-infected mothers than HIV-1-infected mothers had no symptoms, had received no antiretroviral threrapy at conception (85.9% vs 66.7%), and had received no antiretroviral therapy during pregnancy (42.8% vs 19.9%), particularly highly active antiretroviral therapy (HAART) (79.7% vs 46.1%), and they had higher CD4 cell counts near delivery (median, 574 vs 452 cells/mm3; P < .01). If antiretroviral therapy was used, it was started at a later gestational age for HIV-2-infected mothers (median, 28 vs 25 weeks; P < .01). HIV-2-infected mothers were more likely to deliver vaginally (67.9% vs 49.3%) and to breastfeed (3.6% vs 0.6%; P < .01), and their infants less frequently received postexposure prophylaxis. In the period 2000–2007, the proportion with viral load <100 copies/mL at delivery was 90.5% of HIV-2-infected mothers, compared with 76.2% of HIV-1-infected mothers (P = .1). There were 2 cases of transmission: 1 case in 1993 occurred following maternal primary infection, and the other case occurred postnatally in 2002 and involved a mother with severe immune deficiency. The mother-to-child transmission rate for HIV-2 was 0.6% (95% confidence interval, 0.07%–2.2%). Conclusions. Care for HIV-2-infected pregnant women rests on expert opinion. The mother-to-child transmission residual rate (0.07%–2.2%) argues for systematic treatment: protease inhibitor-based HAART for women requiring antiretroviral therapy or for primary infection and simplified prevention of mother-to-child transmission in other instances.</abstract><cop>Oxford</cop><pub>The University of Chicago Press</pub><pmid>20804413</pmid><doi>10.1086/656284</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2010-10, Vol.51 (7), p.833-843 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_888114670 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult AIDS Antiretroviral drugs Biological and medical sciences Cohort Studies Disease transmission Drug therapy Female France Highly active antiretroviral therapy HIV HIV 1 HIV 2 HIV Infections - transmission HIV Infections - virology HIV-2 - isolation & purification HIV/AIDS Human immunodeficiency virus Human immunodeficiency virus 1 Human immunodeficiency virus 2 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infections Infectious Disease Transmission, Vertical Infectious diseases Maternal & child health Medical sciences Mothers Pregnancy Pregnancy Complications, Infectious - virology Protease inhibitors Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral load |
| title | Mother-to-Child Transmission of HIV-2 Infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A19%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mother-to-Child%20Transmission%20of%20HIV-2%20Infection%20from%201986%20to%202007%20in%20the%20ANRS%20French%20Perinatal%20Cohort%20EPF-CO1&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Burgard,%20M.&rft.aucorp=ANRS%20French%20Perinatal%20Cohort%20EPF-CO1&rft.date=2010-10-01&rft.volume=51&rft.issue=7&rft.spage=833&rft.epage=843&rft.pages=833-843&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/656284&rft_dat=%3Cjstor_proqu%3E25742282%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=751864422&rft_id=info:pmid/20804413&rft_jstor_id=25742282&rft_oup_id=10.1086/656284&rfr_iscdi=true |